DE602005027580D1 - Inhibitoren der rna-abhängigen rna-polymerase des hepatitis-c-virus und zusammensetzungen und behandlungen, bei denen diese verwendet werden - Google Patents

Inhibitoren der rna-abhängigen rna-polymerase des hepatitis-c-virus und zusammensetzungen und behandlungen, bei denen diese verwendet werden

Info

Publication number
DE602005027580D1
DE602005027580D1 DE602005027580T DE602005027580T DE602005027580D1 DE 602005027580 D1 DE602005027580 D1 DE 602005027580D1 DE 602005027580 T DE602005027580 T DE 602005027580T DE 602005027580 T DE602005027580 T DE 602005027580T DE 602005027580 D1 DE602005027580 D1 DE 602005027580D1
Authority
DE
Germany
Prior art keywords
hepatitis
virus
treatments
inhibitors
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005027580T
Other languages
English (en)
Inventor
Javier Gonzalez
Tanya Michelle Jewell
Hui Li
Angelica Linton
John Howard Tatlock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE602005027580D1 publication Critical patent/DE602005027580D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
DE602005027580T 2004-08-18 2005-08-05 Inhibitoren der rna-abhängigen rna-polymerase des hepatitis-c-virus und zusammensetzungen und behandlungen, bei denen diese verwendet werden Active DE602005027580D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60261804P 2004-08-18 2004-08-18
PCT/IB2005/002697 WO2006018725A1 (en) 2004-08-18 2005-08-05 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same

Publications (1)

Publication Number Publication Date
DE602005027580D1 true DE602005027580D1 (de) 2011-06-01

Family

ID=35429645

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005027580T Active DE602005027580D1 (de) 2004-08-18 2005-08-05 Inhibitoren der rna-abhängigen rna-polymerase des hepatitis-c-virus und zusammensetzungen und behandlungen, bei denen diese verwendet werden

Country Status (43)

Country Link
US (3) US7151105B2 (de)
EP (1) EP1781662B1 (de)
JP (1) JP4372195B2 (de)
KR (1) KR100851178B1 (de)
CN (2) CN101006092B (de)
AP (1) AP2313A (de)
AR (1) AR050699A1 (de)
AT (1) ATE506364T1 (de)
AU (1) AU2005273619B2 (de)
BR (1) BRPI0514425A (de)
CA (1) CA2577525C (de)
CR (2) CR8935A (de)
CY (1) CY1111480T1 (de)
DE (1) DE602005027580D1 (de)
DK (1) DK1781662T3 (de)
EA (1) EA012605B1 (de)
EC (1) ECSP077264A (de)
ES (1) ES2361845T3 (de)
GE (2) GEP20115305B (de)
GT (1) GT200500221A (de)
HK (1) HK1109617A1 (de)
HN (1) HN2005000449A (de)
HR (1) HRP20110458T1 (de)
IL (2) IL180933A (de)
MA (1) MA28803B1 (de)
MX (1) MX2007001527A (de)
MY (1) MY146123A (de)
NI (1) NI200700043A (de)
NL (1) NL1029755C2 (de)
NO (1) NO20071274L (de)
NZ (1) NZ552874A (de)
PE (1) PE20060677A1 (de)
PL (1) PL1781662T3 (de)
PT (1) PT1781662E (de)
RS (1) RS51794B (de)
SI (1) SI1781662T1 (de)
SV (1) SV2007002202A (de)
TN (1) TNSN07066A1 (de)
TW (1) TWI376379B (de)
UA (1) UA88909C2 (de)
UY (1) UY29068A1 (de)
WO (1) WO2006018725A1 (de)
ZA (1) ZA200700779B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101006092B (zh) * 2004-08-18 2013-04-17 辉瑞有限公司 C型肝炎病毒rna依赖型rna聚合酶的抑制剂、以及使用该抑制剂的组合物和治疗剂
WO2007023381A1 (en) * 2005-08-24 2007-03-01 Pfizer Inc. Methods for the preparation of hcv polymerase inhibitors
US8258116B2 (en) 2007-05-04 2012-09-04 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
EP2008996A1 (de) * 2007-06-27 2008-12-31 Syngeta Participations AG Verfahren zur Herstellung von Pyrazolen
CA2724523A1 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
LT2320905T (lt) 2008-08-11 2017-09-11 Glaxosmithkline Llc Naujieji adenino dariniai
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
BRPI0917458A2 (pt) 2008-08-11 2015-12-01 Glaxosmithkline Llc composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
EP2325173A1 (de) 2009-11-19 2011-05-25 Bayer CropScience AG Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden
AU2010333656B2 (en) * 2009-12-18 2015-08-27 Boehringer Ingelheim International Gmbh HCV combination therapy
PT2534149E (pt) 2010-02-10 2014-12-23 Glaxosmithkline Llc Maleato de 6-amino-2-{[(1s)-1-metilbutil]oxi}-9-[5-(1- piperidinil)pentil]-7,9-di-hidro-8h-purin-8-ona
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
WO2011144549A1 (en) * 2010-05-20 2011-11-24 Bayer Cropscience Ag Method for manufacturing 1 - alkyl - 3 - difluormethyl - 5 - hydroxypyrazoles
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
FR2972452B1 (fr) * 2011-03-09 2013-03-15 Rhodia Operations Procede de preparation du difluoroacetonitrile et de ses derives
MX348274B (es) 2012-05-14 2017-06-02 Bayer Cropscience Ag Procedimiento de preparacion de cloruros de 1-alquil-3-fluoroalqui l-1h-pirazol-4-carbonilo.
WO2014081878A2 (en) 2012-11-21 2014-05-30 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
KR102261967B1 (ko) 2013-01-17 2021-06-07 바이엘 크롭사이언스 악티엔게젤샤프트 5-플루오로-1-메틸-3-디플루오로메틸-1h-피라졸-4-카브알데히드 제조 방법
CN105073735B (zh) 2013-02-06 2018-08-14 拜耳作物科学股份公司 作为害虫防治剂的卤素取代的吡唑衍生物
TW201540705A (zh) 2014-01-03 2015-11-01 拜耳作物科學股份有限公司 做為殺蟲劑之新穎吡唑基雜芳基醯胺類
EP3097081B1 (de) 2014-01-24 2018-01-10 Bayer CropScience Aktiengesellschaft Methode zur herstellung von 1-alkyl-3-difluoromethyl-5-fluor-1h-pyrazole-4-carbaldehyden und 1-alkyl-3-difluoromethyl-5-fluor-1h-pyrazole-4-carboxylaten
RU2676684C2 (ru) 2014-02-20 2019-01-10 ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА
US9932314B2 (en) 2014-06-03 2018-04-03 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as T-type calcium channel blockers
EP3218377B1 (de) 2014-11-13 2022-04-13 GlaxoSmithKline Biologicals SA Zur behandlung von allergischen erkrankungen und anderen entzündlichen zuständen geeignete adenin derivate
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
CN113549110A (zh) 2016-04-07 2021-10-26 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
JP6997420B2 (ja) 2016-08-15 2022-01-17 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 有害生物防除剤としての縮合二環式ヘテロ環誘導体
EP3301094A1 (de) * 2016-09-30 2018-04-04 Mutabilis Heterocyclische verbindungen und deren verwendung zur vorbeugung oder behandlung von bakteriellen infektionen
JP6931701B2 (ja) 2016-12-16 2021-09-08 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｔ型カルシウムチャンネルブロッカーを含有する薬学的合剤
JP6972144B2 (ja) 2017-02-06 2021-11-24 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd １−アリール−１−トリフルオロメチルシクロプロパンを合成するための新規な方法
WO2019068572A1 (de) 2017-10-04 2019-04-11 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2019069269A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited INTERFERON GENE STIMULATOR MODULATORS USEFUL IN THE TREATMENT OF HIV
JP7291130B2 (ja) 2017-10-05 2023-06-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
WO2019175046A1 (de) 2018-03-12 2019-09-19 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
US20210169080A1 (en) 2018-04-20 2021-06-10 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CN112194620B (zh) * 2020-12-04 2021-02-26 苏州开元民生科技股份有限公司 一种2-乙基-4-氰基吡啶的制备方法
CN113563167B (zh) * 2021-07-16 2023-09-08 南通华祥医药科技有限公司 一种2-甲基-1-四氢萘酮的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
DE2155360C3 (de) * 1971-11-08 1980-04-03 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern
CA1144937A (en) 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US4326058A (en) 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
AU688344B2 (en) 1993-07-19 1998-03-12 Mitsubishi-Tokyo Pharmaceuticals, Inc. Hepatitis C virus proliferation inhibitor
US5808062A (en) 1993-11-19 1998-09-15 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
EP0729464A1 (de) 1993-11-19 1996-09-04 PARKE, DAVIS & COMPANY 5,6-dihydropyron derivate als protease inhibitoren und antivirusmitteln
US5504104A (en) 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
MD1560G2 (ro) 1993-11-19 2001-07-31 Parke, Davis & Company Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri
US5789440A (en) 1993-11-19 1998-08-04 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
KR20010085780A (ko) 1998-09-11 2001-09-07 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｈｉｖ 프로테아제 억제제
US6512006B1 (en) 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (de) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis C Virus (HCV) NS5B RNA Polymerase und davon abgeleitete Mutanten
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
CN101006092B (zh) * 2004-08-18 2013-04-17 辉瑞有限公司 C型肝炎病毒rna依赖型rna聚合酶的抑制剂、以及使用该抑制剂的组合物和治疗剂

Also Published As

Publication number Publication date
US20070015764A1 (en) 2007-01-18
HRP20110458T1 (hr) 2011-07-31
ES2361845T3 (es) 2011-06-22
SV2007002202A (es) 2007-03-20
SI1781662T1 (sl) 2011-07-29
MX2007001527A (es) 2007-03-27
CN101538268A (zh) 2009-09-23
CN101006092B (zh) 2013-04-17
ZA200700779B (en) 2008-11-26
UY29068A1 (es) 2006-03-31
AR050699A1 (es) 2006-11-15
ECSP077264A (es) 2007-04-26
TWI376379B (en) 2012-11-11
EA012605B1 (ru) 2009-10-30
EA200700338A1 (ru) 2007-08-31
NL1029755C2 (nl) 2006-10-18
CA2577525C (en) 2010-03-30
KR100851178B1 (ko) 2008-08-08
GEP20115305B (en) 2011-10-10
US20060122399A1 (en) 2006-06-08
AU2005273619B2 (en) 2009-05-28
CN101006092A (zh) 2007-07-25
CR8935A (es) 2007-07-24
IL192919A0 (en) 2009-02-11
GT200500221A (es) 2006-06-21
CR20110153A (es) 2011-04-26
PL1781662T3 (pl) 2011-08-31
AP2313A (en) 2011-10-31
ATE506364T1 (de) 2011-05-15
TNSN07066A1 (fr) 2008-06-02
IL180933A (en) 2011-08-31
MY146123A (en) 2012-06-29
IL180933A0 (en) 2007-07-04
JP4372195B2 (ja) 2009-11-25
HK1109617A1 (en) 2008-06-13
CN101538268B (zh) 2011-07-27
US7622605B2 (en) 2009-11-24
UA88909C2 (ru) 2009-12-10
TW200612898A (en) 2006-05-01
NZ552874A (en) 2010-04-30
WO2006018725A1 (en) 2006-02-23
EP1781662A1 (de) 2007-05-09
NL1029755A1 (nl) 2006-02-21
JP2008509984A (ja) 2008-04-03
AP2007003918A0 (en) 2007-02-28
KR20070044057A (ko) 2007-04-26
PE20060677A1 (es) 2006-08-11
DK1781662T3 (da) 2011-06-27
US20090281122A1 (en) 2009-11-12
GEP20094751B (en) 2009-08-10
PT1781662E (pt) 2011-07-01
MA28803B1 (fr) 2007-08-01
US7151105B2 (en) 2006-12-19
BRPI0514425A (pt) 2008-06-10
EP1781662B1 (de) 2011-04-20
US8268835B2 (en) 2012-09-18
NI200700043A (es) 2008-01-02
HN2005000449A (es) 2009-10-30
CA2577525A1 (en) 2006-02-23
AU2005273619A1 (en) 2006-02-23
CY1111480T1 (el) 2015-08-05
NO20071274L (no) 2007-05-14
RS51794B (en) 2011-12-31

Similar Documents

Publication Publication Date Title
DE602005027580D1 (de) Inhibitoren der rna-abhängigen rna-polymerase des hepatitis-c-virus und zusammensetzungen und behandlungen, bei denen diese verwendet werden
CL2007003250A1 (es) Compuestos derivados de isoquinolina, inhibidores del virus de hepatitis c; composicion farmaceutica; y uso para el tratamiento de una infeccion por vhc.
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140254A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007092888A3 (en) Hcv ns5b inhibitors
IL188320A (en) Macrocyclic inhibitors of the hepatitis c virus, pharmaceutical preparations that include them and their production
WO2008051477A3 (en) Hcv ns3 protease inhibitors
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
NL1025544A1 (nl) Remmers van rna-afhankelijk rna-polymerase van hepatitis-c-virus en preparaten en behandelingen waarbij ze worden gebruikt.
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
IL188227A (en) Macrocyclic compounds, combinations and pharmaceutical preparations containing them, their use as hepatitis C virus inhibitors and processes for their preparation
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
DE602006018970D1 (de) Hunde-influenza-virus und relevante zusammensetzungen und anwendungsverfahren
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.
AU2003224371A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
HK1134676A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same c